EVR Research LP Grows Stock Position in GoodRx Holdings, Inc. $GDRX

Key Points

• EVR Research LP increased its ownership in GoodRx Holdings, Inc. by 243.3%, acquiring a total of 1,300,000 shares valued at approximately $5.73 million.
• GoodRx's recent earnings report showed an EPS of $0.09, missing the consensus estimate by $0.01, amidst a 1.2% year-over-year revenue growth.
• Several analysts have recently adjusted their ratings and target prices for GoodRx, with the average target price now set at $5.80, indicating a mix of buy and hold ratings from various analysts.

EVR Research LP lifted its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 243.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,300,000 shares of the company's stock after purchasing an additional 921,337 shares during the quarter. GoodRx accounts for approximately 1.6% of EVR Research LP's holdings, making the stock its 17th biggest position. EVR Research LP owned approximately 0.34% of GoodRx worth $5,733,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in GoodRx by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 8,624,872 shares of the company's stock worth $38,036,000 after buying an additional 251,833 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after buying an additional 369,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of GoodRx by 16.7% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,434,625 shares of the company's stock valued at $6,327,000 after purchasing an additional 205,789 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of GoodRx by 303.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company's stock valued at $4,936,000 after purchasing an additional 798,261 shares during the period. Finally, Raymond James Financial Inc. grew its stake in shares of GoodRx by 54.6% during the 1st quarter. Raymond James Financial Inc. now owns 830,950 shares of the company's stock valued at $3,664,000 after purchasing an additional 293,420 shares during the period. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Stock Down 0.2%

Shares of GDRX traded down $0.01 during midday trading on Friday, reaching $4.35. 1,569,793 shares of the stock were exchanged, compared to its average volume of 6,053,919. GoodRx Holdings, Inc. has a 52 week low of $3.31 and a 52 week high of $8.38. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. The company's 50 day moving average is $4.57 and its two-hundred day moving average is $4.49. The company has a market capitalization of $1.51 billion, a P/E ratio of 43.50, a PEG ratio of 1.90 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The company had revenue of $203.07 million for the quarter, compared to analysts' expectations of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 earnings per share. On average, sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.53% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Raymond James Financial downgraded GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. UBS Group cut their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. The Goldman Sachs Group lowered their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $6.00 price objective on shares of GoodRx in a report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $5.80.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.